Market Assessment for a Palladium Membrane Deuteration Reactor

钯膜氘化反应堆的市场评估

• 批准号: 538497-2019
• 负责人: Berlinguette, Curtis
• 金额: $ 1.09万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=675464
• 关键词: Market; Assessment; Palladium; Membrane; Deuteration

Our team is developing an electrochemical reactor that leverages the unique properties of a thin palladium membrane to perform reductive deuteration on organic substrates. Our reactor is favourable compared to known synthetic methods because: i) the reactor uses benign reagents; ii) the reactions proceed at room temperature and pressure; iii) the products are produced quantitatively; iv) the reaction is site-selective for certain bonds; v) no product separation is required. This system has the potential to benefit to the pharmaceutical industry because deuteration of a drug can slow the metabolism of a bioactive molecule and increase the overall efficacy. This link between deuteration and the properties for bio-active molecules is established, and the United States Food and Drug Administration approved the first deuterated drug, deutetetrabenazine, in 2017. Several other deuterated versions of common drugs are currently in phase II and III clinical trials. This proposal outlines our plan to undertake a market study in conjunction with UBC's University Industry Liaison Office and Adventus Research Consultants (Guelph, ON) to better understand the market potential of our invention. This study will encompass both primary and secondary research. The final deliverable will be a report from Adventus that informs our commercialization strategy as we develop the technology.

我们的团队正在开发一种电化学反应器，该反应器利用薄钯膜的独特性能在有机基质上进行还原氘代。与已知的合成方法相比，我们的反应器是有利的，因为：i）反应器使用良性试剂; ii）反应在室温和压力下进行; iii）产物是定量产生的; iv）反应对某些键是位点选择性的; v）不需要产物分离。该系统有可能对制药行业有益，因为药物的氘代可以减缓生物活性分子的代谢并增加整体功效。氘化与生物活性分子性质之间的联系已经建立，美国食品和药物管理局于2017年批准了第一种氘化药物氘代丁苯那嗪。其他几种常见药物的氘化版本目前正在进行II期和III期临床试验。该提案概述了我们与UBC大学工业联络办公室和Adventus研究顾问公司（圭尔夫，ON）一起进行市场研究的计划，以更好地了解我们发明的市场潜力。这项研究将包括初级和次级研究。最终的交付成果将是Adventus的一份报告，该报告将在我们开发该技术时告知我们的商业化战略。